Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
2020
PURPOSEAxicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of durable remission rates of appr...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
17
References
69
Citations
NaN
KQI